Nivolumab alone or with ipilimumab in recurrent small cell lung cancer (SCLC): 2-year survival and apdated analyses from the CheckMate 032 trial Meeting Abstract
| Authors: | Hellmann, M.; Antonia, S.; Ponce, S.; Ott, P.; Calvo, E.; Taylor, M.; Ready, N.; Hann, C.; De Braud, F.; Eder, J. P.; Jäger, D.; Ascierto, P.; Horn, L.; Amin, A.; Evans, J.; Moreno, V.; Atmaca, A.; Pillai, R.; Bhosle, J.; Bono, P.; Reguart, N.; Schneider, J.; Brossart, P.; Diamond, J.; Sharma, P.; Lassen, U.; Lin, C. S.; Tschaika, M.; Selvaggi, G.; Spigel, D. |
| Abstract Title: | Nivolumab alone or with ipilimumab in recurrent small cell lung cancer (SCLC): 2-year survival and apdated analyses from the CheckMate 032 trial |
| Meeting Title: | IASLC 17th World Conference on Lung Cancer |
| Keywords: | ipilimumab; pd-l1; sclc; nivolumab |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 12 |
| Issue: | 1 Suppl. |
| Meeting Dates: | 2016 Dec 4-7 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-01-01 |
| Start Page: | S393 |
| End Page: | S394 |
| Language: | English |
| ACCESSION: | WOS:000413055800427 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2016.11.446 |
| Notes: | Meeting Abstract: MA09.05 -- Source: Wos |
